XML 67 R57.htm IDEA: XBRL DOCUMENT v3.21.2
License Funding and Other Agreements Related to the CVR - Additional Information (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 27, 2021
Oct. 31, 2020
Feb. 28, 2021
Nov. 30, 2020
May 31, 2019
Jun. 30, 2021
Jun. 30, 2021
Mar. 23, 2017
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Exercised Investment Right and Purchased             $ 10.0  
Estimated fair value of the CVR liability           $ 0.0 0.0  
Funding Agreement                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Qualifying expenses             0.3  
National Institute of Health                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Grant term         5 years      
Grants receivable         $ 1.5      
Qualifying expenses           0.3    
Qualifying expenses on cumulative basis             1.3  
National Institute of Health | Funding Agreement                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Qualifying expenses           0.1 0.5  
Qualifying expenses on cumulative basis             1.3  
Contingent Value Rights Agreement | C O V I D19                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Total fees and expenses related to clinical trials   $ 1.1         3.0  
Post Exposure Prophylaxis in adults     In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment          
Increase decrease in estimated fair value of CVR liability       $ 0.4        
Estimated fair value of the CVR liability       $ 0.6   $ 0.0 $ 0.0  
Novartis License Agreement | Novartis International Pharmaceutical Ltd.                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
License agreement termination description On, July 27, 2021, the Company sent Novartis a termination notice. Termination will automatically take effect as of 60 days from the date of delivery of the termination notice to Novartis, but in no event later than October 1, 2021 without any further notice or action required of either Novartis or the Company.           The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days’ prior written notice.  
Novartis License Agreement | Novartis International Pharmaceutical Ltd. | Maximum                
Research And Development Arrangement Contract To Perform For Others [Line Items]                
Aggregate amount payable upon satisfaction of clinical milestones               $ 4.3
Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved               24.0
Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved               18.0
Aggregate amount payable upon satisfaction of commercial milestones               $ 125.0